It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Glioblastoma is a highly aggressive brain tumor for which there is no cure. The metabolic enzyme 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4 (PFKFB4) is essential for glioblastoma stem-like cell (GSC) survival but its mode of action is unclear. Understanding the role of PFKFB4 in tumor cell survival could allow it to be leveraged in a cancer therapy. Here, we show the importance of PFKFB4 for glioblastoma growth in vivo in an orthotopic patient derived mouse model. In an evaluation of patient tumor samples of different cancer entities, PFKFB4 protein was found to be overexpressed in prostate, lung, colon, mammary and squamous cell carcinoma, with expression level correlating with tumor grade. Gene expression profiling in PFKFB4-silenced GSCs revealed a downregulation of hypoxia related genes and Western blot analysis confirmed a dramatic reduction of HIF (hypoxia inducible factor) protein levels. Through mass spectrometric analysis of immunoprecipitated PFKFB4, we identified the ubiquitin E3 ligase, F-box only protein 28 (FBXO28), as a new interaction partner of PFKFB4. We show that PFKFB4 regulates the ubiquitylation and subsequent proteasomal degradation of HIF-1α, which is mediated by the ubiquitin ligase activity of FBXO28. This newly discovered function of PFKFB4, coupled with its cancer specificity, provides a new strategy for inhibiting HIF-1α in cancer cells.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Balss, Jörg 1 ; Bethke, Frederic 1 ; Pusch, Stefan 2 ; Christen, Stefan 3 ; Hielscher, Thomas 4 ; Schnölzer, Martina 5 ; Fletcher, Michael N. C. 6 ; Habel, Antje 7 ; Tessmer, Claudia 8 ; Brenner, Lisa-Marie 1 ; Göttmann, Mona 1 ; Capper, David 9 ; Herold-Mende, Christel 10 ; von Deimling, Andreas 2 ; Fendt, Sarah-Maria 3 ; Goidts, Violaine 1
1 German Cancer Research Center (DKFZ), Junior Research Group “Brain Tumor Translational Targets”, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
2 Ruprecht-Karls-University Heidelberg, Department of Neuropathology, Institute of Pathology, Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373); German Cancer Research Center (DKFZ), German Consortium of Translational Cancer Research (DKTK), Clinical Cooperation Unit Neuropathology, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
3 VIB Center for Cancer Biology, VIB, Laboratory of Cellular Metabolism and Metabolic Regulation, Leuven, Belgium (GRID:grid.511459.d); KU Leuven and Leuven Cancer Institute (LKI), Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
4 German Cancer Research Center, Department of Biostatistics, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
5 German Cancer Research Center (DKFZ), Functional Proteome Analysis, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
6 German Cancer Research Center (DKFZ), Department of Structural and Functional Genomics, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
7 Ruprecht-Karls-University Heidelberg, Department of Neuropathology, Institute of Pathology, Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373)
8 German Cancer Research Center (DKFZ), Antibody Unit, Genomics and Proteomics Core Facility, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
9 Ruprecht-Karls-University Heidelberg, Department of Neuropathology, Institute of Pathology, Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373); German Cancer Research Center (DKFZ), German Consortium of Translational Cancer Research (DKTK), Clinical Cooperation Unit Neuropathology, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584); Charité Universitätsmedizin, Corporate Member of Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health, Department of Neuropathology, Berlin, Germany (GRID:grid.7468.d) (ISNI:0000 0001 2248 7639)
10 University Hospital Heidelberg, INF 400, Division of Neurosurgical Research, Department of Neurosurgery, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)




